Recombinant CCR4 (Mogamulizumab Biosimilar) antibody

Catalog No. ABIN7795114

This anti-CCR4 (Mogamulizumab Biosimilar) antibody is a Humanized Monoclonal antibody detecting CCR4 (Mogamulizumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant CCR4 (Mogamulizumab Biosimilar) antibody (ABIN7795114)

Target: CCR4 (Mogamulizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CCR4 (Mogamulizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody

Characteristics: Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous, these cancers typically affect the skin, causing various types of skin lesions. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CCR4

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CCR4 (Mogamulizumab Biosimilar)

Target: CCR4 (Mogamulizumab Biosimilar)

Alternative Name: Mogamulizumab Biosimilar

Target Type: Biosimilar